Biologics

Three spine surgeons from across the U.S. discuss where they see the biggest opportunities in spinal biologics and disc generation.

Aziyo Biologics launched OsteGro, an allograft bone matrix designed to support new bone growth in procedures such as hip reconstruction, bone fracture repair and spinal fusion.

Indianapolis-based orthopedic surgeon Greg Merrell, MD, treated the first U.S. patient in Cartiva's GRIP 2 study, evaluating the safety and effectiveness of the Cartiva Synthetic Cartilage Implant to treat osteoarthritis of the thumb. 

The global stem cell therapy market is projected to grow at a compound annual growth rate of 36.52 percent between 2017 and 2021, according to an analysis by Wise Guy Reports.

KICVentures acquired Amend Surgical, a company developing synthetic bioactive glass products.

Orthobiologics company Cerapedics received FDA approval to initiate a study of P-15L Peptide Enhanced Bone Graft compared to autograft in transforaminal lumbar interbody fusion surgery for degenerative disc disease.

Gregory Lutz, MD, and Kevin Pauza, MD, launched a new study to examine the clinical effectiveness of Discseel, a treatment to restore and regrow damaged discs in the spine.

Mesenchymal stromal cells have shown promise for regenerative medicine, according to the Journal of Orthopaedics. They may improve spinal fusion.

 that demineralized bone matrix activity induces bone when implanted ectopically into the muscle or under the skin due to bone morphogenetic proteins.

The use of biologics before and during pregnancy is not associated with an increased risk of preterm delivery or small-for-gestational-age births, a study in Annals of the Rheumatic Diseases finds.